Remdesivir

Generic Name: Remdesivir

Brand Names: Veklury

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₅N_₆O_₈P

CAS Number: 1809249-37-3

Unique Ingredient Identifier: 3QKI37EEHE

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp)...

Indication: Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, ...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)

Associated Therapies: -

Clinical Trials

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Phase 3

Completed

Conditions: Covid19

Interventions: Biological: Remdesivir
Biological: Remdesivir Placebo
Drug: Corticosteroid

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 87

Registration Number: NCT06729593

Locations: 🇺🇸
UCSF Medical Center (Site 203-001), Moffit-Long Hospital, 505 Parnassus Ave., San Francisco, California, United States
🇺🇸
Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr., Stanford, California, United States
🇺🇸
Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue, Tucson, Arizona, United States

and more 37 locations

An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.

Phase 4

Recruiting

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Drug: Remdesivir

First Posted Date: 2023-06-22

Last Posted Date: 2024-12-10

Lead Sponsor: University of Derby

Target Recruit Count: 72

Registration Number: NCT05911906

Locations: 🇬🇧
Derbyshire Community Health Services NHS Foundation Trust, Chesterfield, United Kingdom
🇬🇧
Royal Derby Hospital (UHDB), Derby, United Kingdom
🇬🇧
University of Exeter / Royal Devon University Healthcare NHS FT, Exeter, United Kingdom

and more 1 locations

Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients

Phase 4

Completed

Conditions: COVID-19

Interventions: Drug: Casirivimab and Imdevimab Drug Combination
Drug: Remdesivir
Drug: Favipiravir

First Posted Date: 2022-08-16

Last Posted Date: 2023-07-25

Lead Sponsor: Mansoura University Hospital

Target Recruit Count: 265

Registration Number: NCT05502081

Locations: 🇪🇬
El-gomhoria St, Mansoura, El-dkhalia, Egypt

OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

Completed

Conditions: Duration of Hospitalization
Clinical Manifestation of COVID-19

First Posted Date: 2022-02-03

Last Posted Date: 2022-02-03

Lead Sponsor: Bernadette Dian Novita, MD.,PhD

Target Recruit Count: 87

Registration Number: NCT05222113

Locations: 🇮🇩
Gotong Royong Surabaya Hospital, Surabaya, East Java, Indonesia

Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Favipiravir
Drug: Remdesivir

First Posted Date: 2022-01-11

Last Posted Date: 2022-01-11

Lead Sponsor: Promomed, LLC

Target Recruit Count: 217

Registration Number: NCT05185284

Locations: 🇷🇺
Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation
🇷🇺
Smolensk clinical hospital №1, Smolensk, Russian Federation
🇷🇺
State Clinical Hospital №50, Moscow, Russian Federation

and more 3 locations

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Nitazoxanide
Drug: Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Hydroxychloroquine
Other: No treatment
Drug: Monoclonal antibodies
Drug: Fluoxetine
Drug: Molnupiravir
Drug: Sotrovimab
Drug: Ensitrelvir
Drug: Favipiravir
Drug: Ivermectin
Drug: Remdesivir
Drug: Atilotrelvir/ritonavir
Drug: Metformin
Drug: Nirmatrelvir/ritonavir
Drug: Nirmatrelvir

First Posted Date: 2021-09-13

Last Posted Date: 2024-10-28

Lead Sponsor: University of Oxford

Target Recruit Count: 3800

Registration Number: NCT05041907

Locations: 🇳🇵
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦
Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

Public Health Emergency: SOLIDARITY TRIAL Philippines

Not Applicable

Completed

Conditions: Covid19

Interventions: Drug: Remdesivir
Drug: Lopinavir / Ritonavir
Drug: Hydroxychloroquine
Drug: Acalabrutinib
Drug: Interferon beta-1a

First Posted Date: 2021-08-27

Last Posted Date: 2022-03-02

Lead Sponsor: University of the Philippines

Target Recruit Count: 1314

Registration Number: NCT05024006

Locations: 🇵🇭
Chinese General Hospital, Manila, Metro Manila, Philippines
🇵🇭
UP - Philippine General Hospital, Manila, Metro Manila, Philippines
🇵🇭
San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines

and more 22 locations

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Placebo
Drug: Danicopan
Drug: Remdesivir

First Posted Date: 2021-08-03

Last Posted Date: 2023-06-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 201

Registration Number: NCT04988035

Locations: 🇺🇸
Great Lakes Clinical Trials, Chicago, Illinois, United States
🇺🇸
Nuvance Health Danbury Hospital - Infectious Disease, Danbury, Connecticut, United States
🇺🇸
Kern Medical Center, Bakersfield, California, United States

and more 36 locations

SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)

Phase 4

Conditions: Covid19

Interventions: Drug: Remdesivir

First Posted Date: 2021-07-27

Last Posted Date: 2022-07-15

Lead Sponsor: Clinical Urology and Epidemiology Working Group

Target Recruit Count: 202

Registration Number: NCT04978259

Locations: 🇫🇮
University of Helsinki, Helsinki, Finland

Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

Phase 3

Withdrawn

Conditions: COVID-19 Pneumonia

Interventions: Drug: Baricitinib
Drug: Dexamethasone
Drug: Remdesivir

First Posted Date: 2021-07-21

Last Posted Date: 2024-04-09

Lead Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

Registration Number: NCT04970719

Locations: 🇧🇩
Kurigram Adhunik Sadar Hospital, Kurigram, Bangladesh
🇧🇩
Rajshahi Medical College & Hospital, Rajshahi, Bangladesh
🇧🇩
Debidwar Upazila Health Complex, Comilla, Bangladesh

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy